Athersys and Chugai Pharmaceutical have announced a partnership and pharma licensing agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Read the full story

Teva Pharmaceutical Industries has entered into a $120 million pharma licensing agreement that will allow it to distribute and promote a competitor to its own cancer drug, Eagle Pharmaceuticals EP-3102. Read the full story

Philogen entered into a pharma licensing agreement with Pfizer to develop and commercialize empowered antibodies. Read the full story

Iroko Pharmaceuticals signed a licensing agreement with Aspen Pharma for the exclusive rights to register and market ZORVOLEX (diclofenac) capsules in Australia and New Zealand. Read the full story

Medivation has signed pharma licensing deal for exclusive worldwide rights to CureTech's late-stage clinical molecule pidilizumab (CT-011), an immune modulatory anti-PD-1 monoclonal antibody. Read the full story

Sutro Biopharma has entered a pharma deal and option agreement with Celgene to discover and develop antibodies and antibody drug conjugates. Read the full story

IMS Health becomes pharma partner with UCB to help deliver greater business insights and improved operations, leveraging IMS Health’s Nexxus Commercial Application Suite and the IMS One intelligent cloud. Read the full story

Ipsen and Lexicon Pharmaceuticals have entered into an exclusive pharma licensing deal for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Read the full story

Forendo Pharma has entered into a definitive pharma licensing deal for the US development and commercialization rights for fispemifene to Apricus Biosciences. Read the full story

Oxford BioMedica has struck a pharma licensing deal worth $90 million with Novartis to manufacture goods that are needed for a highly experimental cancer research program. Read the full story